Similar articles

Abstract: Background: A major shortcoming in tissue engineered blood vessels (TEBVs) is the lack of healthy and easily attainable smooth muscle cells (SMCs). smooth muscle progenitor cells (SPCs), especially from peripheral blood, may offer an alternative cell source for tissue engineering involving a less invasive harvesting technique. Methods: SPCs were isolated from 5-ml fresh rat peripheral blood by density-gradient centrifugation and cultured for 3 weeks in endothelial growth medium-2-MV (EGM-2-MV) medium containing platelet-derived growth factor-BB (PDGF BB). Before seeded on the synthesized scaffold, SPC-derived smooth muscle outgrowth cell (SOC) phenotypes were assessed by immuno-fluorescent staining, Western blot analysis, and reverse transcription polymerase chain reaction (RT-PCR). The cells were seeded onto the silk fibroin-modified poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) (SF-PHBHH_x) scaffolds by 6×10⁴ cells/cm² and cultured under the static condition for 3 weeks. The growth and proliferation of the seeded cells on the scaffold were analyzed by 3-(4,5-dimethylthiazol-2-yl)-diphenyltetrazolium bromide (MTT) assay, scanning electron microscope (SEM), and 4,6-diamidino-2-phenylindole (DAPI) staining. Results: SOCs displayed specific “hill and valley” morphology, expressed the specific markers of the SMC lineage: smooth muscle (SM) α-actin, calponin and smooth muscle myosin heavy chain (SM MHC) at protein and messenger ribonucleic acid (mRNA) levels. RT-PCR results demonstrate that SOCs also expressed smooth muscle protein 22α (SM22α), a contractile protein, and extracellular matrix components elastin and matrix Gla protein (MGP), as well as vascular endothelial growth factor (VEGF). After seeded on the SF-PHBHH_x scaffold, the cells showed excellent metabolic activity and proliferation. Conclusion: SPCs isolated from peripheral blood can be differentiated into the SMCs in vitro and have an impressive growth potential in the biodegradable synthesized scaffold. Thus, SPCs may be a promising cell source for constructing TEBVs.

[1] Bensinger, W., Singer, J., Appelbaum, F., Lilleby, K., Longin, K., Rowley, S., Clarke, E., Clift, R., Hansen, J., Shields, T., et al., 1993. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood, 81:3158-3163.

[2] Campbell, G.R., Campbell, J.H., 2007. Development of tissue engineered vascular grafts. Curr. Pharm. Biotechnol., 8(1):43-50.

[3] Chen, G., Zhou, P., Mei, N., Chen, X., Shao, Z., Pan, L.F., Wu, C.G., 2004. Silk fibroin modified porous poly(epsilon-caprolactone) scaffold for human fibroblast culture in vitro. J. Mater. Sci. Mater. Med., 15(6):671-677.

[4] Dahl, S.L., Rhim, C., Song, Y.C., Niklason, L.E., 2007. Mechanical properties and compositions of tissue engineered and native arteries. Ann. Biomed. Eng., 35(3):348-355.

[5] Fang, N.T., Xie, S.Z., Wang, S.M., Gao, H.Y., Wu, C.G., Pan, L.F., 2007. Construction of tissue-engineered heart valves by using decellularized scaffolds and endothelial progenitor cells. Chin. Med. J., 120(8):696-702.

[6] Gao, G., Li, Y., Zhang, D., Gee, S., Crosson, C., Ma, J., 2001. Unbalanced expression of VEGF and PDGF in ischemia-induced retinal neovascularization. FEBS Lett., 489(2-3):270-276.

[7] Gao, J., Crapo, P., Nerem, R., Wang, Y., 2008. Co-expression of elastin and collagen leads to highly compliant engineered blood vessels. J. Biomed. Mater. Res. A, 85(4):1120-1128.

[8] Jevon, M., Dorling, A., Hornick, P.I., 2008. Progenitor cells and vascular disease. Cell Prolif., 41(Suppl. 1):146-164.

[9] Kaushal, S., Amiel, G.E., Guleserian, K.J., Shapira, O.M., Perry, T., Sutherland, F.W., Rabkin, E., Moran, A.M., Schoen, F.J., Atala, A., et al., 2001. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat. Med., 7(9):1035-1040.

[10] Liu, J.Y., Swartz, D.D., Peng, H.F., Gugino, S.F., Russell, J.A., Andreadis, S.T., 2007. Functional tissue-engineered blood vessels from bone marrow progenitor cells. Cardiovasc. Res., 75(3):618-628.

[11] Liu, J.Y., Peng, H.F., Andreadis, S.T., 2008. Contractile smooth muscle cells derived from hair-follicle stem cells. Cardiovasc. Res., 79(1):24-33.

[12] Mahoney, W.M., Schwartz, S.M., 2005. Defining smooth muscle cells and smooth muscle injury. J. Clin. Invest., 115(2):221-224.

[13] Mei, N., Zhou, P., Pan, L.F., Chen, G., Wu, C.G., Chen, X., Shao, Z.Z., Chen, G.Q., 2006. Biocompatibility of poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) modified by silk fibroin. J. Mater. Sci. Mater. Med., 17(8):749-758.

[14] Melero-Martin, J.M., Khan, Z.A., Picard, A., Wu, X., Paruchuri, S., Bischoff, J., 2007. In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood, 109(11):4761-4768.

[15] Miano, J.M., Cserjesi, P., Ligon, K.L., Periasamy, M., Olson, E.N., 1994. Smooth muscle myosin heavy chain marks exclusively the smooth muscle lineage during mouse embryogenesis. Circ. Res., 75:803-812.

[16] Nugent, H.M., Edelman, E.R., 2003. Tissue engineering therapy for cardiovascular disease. Circ. Res., 92(10):1068-1078.

[17] Owens, G.K., Kumar, M.S., Wamhoff, B.R., 2004. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev., 84(3):767-801.

[18] Pettengell, R., Morgenstern, G.R., Woll, P.J., Chang, J., Rowlands, M., Young, R., Radford, J.A., Scarffe, J.H., Testa, N.G., Crowther, D., 1993. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood, 82:3770-3777.

[19] Regan, C.P., Manabe, I., Owens, G.K., 2000. Development of a smooth muscle-targeted cre recombinase mouse reveals novel insights regarding smooth muscle myosin heavy chain promoter regulation. Circ. Res., 87:363-369.

[20] Sartore, S., Scatena, M., Chiavegato, A., Faggin, E., Giuriato, L., Pauletto, P., 1994. Myosin isoform expression in smooth muscle cells during physiological and pathological vascular remodeling. J. Vasc. Res., 31:61-81.

[21] Schurgers, L.J., Teunissen, K.J., Knapen, M.H., Kwaijtaal, M., van Diest, R., Appels, A., Reutelingsperger C.P., Cleutjens, J.P., Vermeer, C., 2005. Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler. Thromb. Vasc. Biol., 25(8):1629-1633.

[22] Shanahan, C.M., Proudfoot, D., Farzaneh-Far, A., Weissberg, P.L., 1998. The role of Gla proteins in vascular calcification. Crit. Rev. Eukaryot. Gene Expr., 8(3-4):357-375.

[23] Simper, D., Stalboerger, P.G., Panetta, C.J., Wang, S., Caplice, N.M., 2002. Smooth muscle progenitor cells in human blood. Circulation, 106(10):1199-1204.

[24] Stegemann, J.P., Hong, H., Nerem, R.M., 2005. Mechanical, biochemical, and extracellular matrix effects on vascular smooth muscle cell phenotype. J. Appl. Physiol., 98(6):2321-2327.

[25] Wu, K.H., Liu, Y.L., Zhou, B., Han, Z.C., 2006. Cellular therapy and myocardial tissue engineering: the role of adult stem and progenitor cells. Eur. J. Cardiothorac. Surg., 30(5):770-781.

[26] Wu, X., Rabkin-Aikawa, E., Guleserian, K.J., Perry, T.E., Masuda, Y., Sutherland, F.W., Schoen, F.J., Mayer, J.E., Bischoff, J., 2004. Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cells. Am. J. Physiol. Heart. Circ. Physiol., 287(2):H480-H487.

[27] Yeh, E.T., Zhang, S., Wu, H.D., Körbling, M., Willerson, J.T., Estrov, Z., 2003. Transdifferentiation of human peripheral blood CD34⁺-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation, 108(17):2070-2073.

[28] Zhang, X., Baughman, C.B., Kaplan, D.L., 2008. In vitro evaluation of electrospun silk fibroin scaffolds for vascular cell growth. Biomaterials, 29(14):2217-2227.

[29] Zund, G., Ye, Q., Hoerstrup, S.P., Schoeberlein, A., Schmid, A.C., Grunenfelder, J., Vogt, P., Turina, M., 1999. Tissue engineering in cardiovascular surgery: MTT, a rapid and reliable quantitative method to assess the optimal human cell seeding on polymeric meshes. Eur. J. Cardiothorac. Surg., 15(4):519-524.